Employees from the NMRC
for Hematology of the Russian Ministry of Health presented poster reports at the 67th ASH Annual Meeting and Exposition in Orlando (USA).
A poster titled “Somatic mutations in cancer-related genes in chronic myeloid leukemia patients receiving asciminib” was presented at the 67th ASH Annual Meeting and Exposition in Orlando (USA) on 6-9 December. The author is hematologist Elena Kuzmina from the Clinical Diagnostic Department for Myeloproliferative Diseases, along with co-authors from other clinical and laboratory departments of the NMRC for Hematology.
The poster presented the results of an assessment of somatic mutations in genes associated with myeloid neoplasms in patients with chronic myeloid leukemia. It was established that the presence of these mutations was associated with a significantly poorer response to therapy with the allosteric tyrosine kinase inhibitor asciminib compared to patients without these mutations.
In the photo: Hematologist Delphine Rea from the Saint-Louis University Hospital (Paris) and hematologist Elizabetta Abruzzese from the Sant'Eugenio Clinic (Rome) at the poster.
The topic of the second poster: “Distinctive features of patients with MPN during pregnancy: Thrombotic risk, molecular drivers, and differential outcomes by subtype,” authored by Doctor of Medical Sciences, Head of the Clinical Diagnostic Department for the Standardization of Treatment Methods of Hematological Diseases Anahit Melikyan, with co-authors from this and other clinical and laboratory departments of the NMRC for Hematology.
The report presented outcomes from 150 pregnancies in 110 patients with myeloproliferative neoplasms. It was shown that a more favorable course of pregnancy and its outcomes were observed in patients with essential thrombocythemia compared to patients with polycythemia vera. The results of this study were included in the final presentation “Updates in Obstetric Hematology” at the Highlights of ASH 2026 conference.
ASH is an annual international conference in the field of hematology.
